2025/05/14 by Chen Liu, Mingchen Li, Liu, Chen +9 · 1 voice · 2 citations
Biochemistry, Genetics and Molecular Biology · Computer Science · Medicine · #FOS: Biological sciences #FOS: Computer and information sciences #Glycosylation and Glycoproteins Research #Machine Learning (cs.LG) #Monoclonal and Polyclonal Antibodies Research #Protein purification and stability #Quantitative Methods (q-bio.QM) #cs.LG #q-bio.QM
paper · pdf · doi:10.48550/arxiv.2505.20301
openalex publication_date 2025/05/14 · arxiv published 2025/05/14 · arxiv updated 2025/05/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
A pivotal area of research in antibody engineering is to find effective modifications that enhance antibody-antigen binding affinity. Traditional wet-lab experiments assess mutants in a costly and time-consuming manner. Emerging deep learning solutions offer an alternative by modeling antibody structures to predict binding affinity changes. However, they heavily depend on high-quality complex structures, which are frequently unavailable in practice. Therefore, we propose ProtAttBA, a deep learning model that predicts binding affinity changes based solely on the sequence information of antibody-antigen complexes. ProtAttBA employs a pre-training phase to learn protein sequence patterns, following a supervised training phase using labeled antibody-antigen complex data to train a cross-attention-based regressor for predicting binding affinity changes. We evaluated ProtAttBA on three open benchmarks under different conditions. Compared to both sequence- and structure-based prediction methods, our approach achieves competitive performance, demonstrating notable robustness, especially with uncertain complex structures. Notably, our method possesses interpretability from the attention mechanism. We show that the learned attention scores can identify critical residues with impacts on binding affinity. This work introduces a rapid and cost-effective computational tool for antibody engineering, with the potential to accelerate the development of novel therapeutic antibodies.